biologics segment is expected to capture the majority share (over 65%) of the market by 2035
Similarly, Eric Polley, PhD, a UChicago data science and public health expert, recently led a study published in Nature Cardiovascular Research that used statistical modeling to emulate a clinical trial comparing the effects of four different classes of diabetes medication in patients with moderate cardiovascular risk
As Mounjaro and Zepbound, Tirzepatide has been administered to millions of patients, generating a robust post-market pharmacovigilance dataset unavailable for Retatrutide
Both drugs are synthetic versions of those hormones, designed to activate specific receptors in the body
Here is why this matters for the timeline question
These drugs may also improve heart health in perimenopausal and menopausal women by lowering blood pressure, reducing LDL cholesterol, and increasing insulin sensitivity, counteracting the increased risk of heart disease that occurs as estrogen levels decline
